Finance
Germany Risks Missing Out on New Drugs, AstraZeneca CEO Tells Paper
Published by Global Banking & Finance Review®
Posted on April 21, 2026
2 min readLast updated: April 21, 2026
Add as preferred source on GoogleQuick Summary
AstraZeneca CEO Pascal Soriot warns that Germany’s cost‑control reforms in statutory health insurance risk delaying or blocking the launch of new drugs, potentially sidelining Germany in pharmaceutical innovation amid rising U.S. pressure and shifting investment priorities.
AstraZeneca CEO: German Drug Spending Cuts May Restrict Access to New Medicines
Potential Impact of German Pharmaceutical Spending Policies
FRANKFURT, April 21 (Reuters) - AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new drugs that the Anglo-Swedish drugmaker plans to launch if the nation sticks with plans to keep spending on pharmaceuticals in check.
Concerns Over Product Launches
“When we can't launch some of those products, it's really a problem," he was quoted as saying by the newspaper. "It's going to be very hard for us, we're going to be attacked, but in the end we will have no choice, also because of the pressure in the U.S.”
Government Measures and Proposals
Germany's coalition government last week announced a raft of measures to overhaul the statutory health insurance system to reduce a looming funding gap by 20 billion euros.
Under the proposals, an existing mandatory discount on patented drugs could become steeper under a variable mechanism that depends on overall drug expenditures and on contributions paid.
"The proposed regulation is a dangerous backward step," said Soriot.
International Pricing Pressures
U.S. President Donald Trump has been pushing to lower the cost of prescription drugs in the United States, which has traditionally paid significantly more than other wealthy countries. He has sought to tie the cost for Americans to what is paid elsewhere, including in Europe, known as most-favoured-nation pricing.
Delayed Launches in Europe
Drugmakers have delayed launches of some new medicines in Europe in response to the U.S. pressure, a Reuters report showed last month.
“It's really not a threat. If you look at the mathematics, you realize that the business impact is so big, we have no choice," Soriot was quoted as saying.
Risks to European Pharmaceutical Industry
He warned that Europe overall was at risk of becoming a place for sales offices for the industry and no longer for research, development and manufacturing.
(Reporting by Ludwig Burger, Editing by Louise Heavens)
Key Takeaways
- •Germany’s proposed reform to tighten mandatory rebates and spending caps could deter AstraZeneca from launching new drugs there, the CEO says.
- •Without more favorable conditions, Europe—and Germany in particular—could lose out on R&D, manufacturing and access to innovative therapies amid U.S. Most‑Favoured‑Nation pricing pressure.
- •Germany’s health insurance system faces looming deficits—projected at €15–40 billion by 2030—prompting reforms that may inadvertently undermine the pharmaceutical sector’s investment incentives.
Frequently Asked Questions about Germany risks missing out on new drugs, AstraZeneca CEO tells paper
1Why does AstraZeneca believe Germany risks missing new drugs?
AstraZeneca's CEO said strict spending controls may force the company to delay launches of new medicines in Germany.
2What changes are proposed in Germany's drug spending policy?
The German government plans measures to limit healthcare costs, including potentially steeper mandatory discounts on patented drugs.
3How might U.S. drug pricing pressure affect Europe?
Pressure from U.S. pricing reforms has led some drugmakers to delay medicine launches in Europe, including Germany.
4What industry impact does AstraZeneca foresee for Europe?
AstraZeneca's CEO warned Europe could become only a sales hub, losing its research and manufacturing roles in pharmaceuticals.
5Who reported the statements from AstraZeneca's CEO?
Handelsblatt reported the CEO’s concerns, with additional context provided by Reuters.
